Evidence map›Paper›PMID 40091621›Full record

ReviewFuture medicinal chemistry2025

Expecting medication misuse: a proactive approach to drug discovery to prevent fatal overdose.

Eileen Carry, Ariane Vasilatis, Anna Laroche Johnson, Jake William Ryan

Abstract readReview
In one paragraph

Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eileen CarryDepartment of Drug Discovery, Zena Therapeutics Inc., North Brunswick, NJ, USA.
Ariane VasilatisDepartment of Drug Discovery, Zena Therapeutics Inc., North Brunswick, NJ, USA.
Anna Laroche JohnsonDepartment of Biomedical Research Summer Internship Program, National Institute of Drug Abuse, North Brunswick, NJ, USA.ORCID 0009-0001-4930-0958
Jake William RyanDepartment of Biomedical Research Summer Internship Program, National Institute of Drug Abuse, North Brunswick, NJ, USA.

Funding

Development of compound RUEC2-118, a novel partial GABAAR positive modulator, a fast-acting treatment for general anxiety and panic disorder, to prevent opioid and benzodiazepine overdose fatalities.R41DA058472 · NIDA · ZENA THERAPEUTICS INC. · PI CARRY, EILEEN · 2023 to 2024
$368k
NIDA NIH HHS R41 DA058472NIH HHS R43 DA058472–01
6 · The paper itself

Abstract

Misuse of central nervous system (CNS) depressants (alprazolam, fentanyl, etc.) is a major cause of fatal overdose, with a high prevalence of deaths involving polydrug interactions from the victim's own prescriptions. Thus, there is an urgent need to improve the safety of CNS depressants to prevent fatalities. Pharmacological pursuits aiming to prevent harm through the design of non-addictive alternatives have either failed before clinical trials or produced mediocre treatment alternatives. Therefore, we propose a new perspective for medicinal chemists: rather than aiming to prevent misuse, we must design new central nervous system (CNS) depressants under the expectation of misuse. By shifting the design focus to partial modulators rather than full agonists, we can develop novel chemical entities (NCEs) that intrinsically minimize physical harm caused by misuse without sacrificing therapeutic efficacy. In this perspective, we provide an overview of the two most widely misused classes of medications (opioid and GABA

Indexed as

Analgesics, OpioidDrug DiscoveryDrug OverdoseAnimalsHumansReceptors, GABA-AAnalgesics, OpioidReceptors, GABA-AbenzodiazepinesDrug discoveryGABAA receptorsmedication misuseopioid use disorderoverdoserespiratory depressionwithdrawal

Identifiers

PMID40091621
PMCPMC11938974

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.